- Oops!Something went wrong.Please try again later.
Results from the Canadian Immunization Research Network (CIRN) showed that one dose of AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine was 82% effective against hospitalization or death caused by the Beta/Gamma COVID-19 variants.
Dubbed Vaxzevria, the vaccine also showed a high level of effectiveness against the Delta (B.617.2, 'Indian') and Alpha (B.1.1.7, 'Kent') variants with 87% and 90% reduction in hospitalizations or deaths, respectively.
The data was published as a pre-print.
Follow-up time was insufficient to report on the vaccine's effectiveness after two doses; other studies have shown increased effectiveness following the indicated two-dose schedule.
Vaccine effectiveness against any symptomatic disease was 50% against the Beta/Gamma variants and 70% and 72% against the Delta and Alpha variants.
A Phase 1/2 trial carried out by the University of Oxford and the University of the Witwatersrand in January had shown limited efficacy against mild disease primarily due to the Beta variant.
The analysis included around 70,000 individuals who tested positive for the infection from December 2020 to May 2021 in Ontario, Canada, with 28,705 (6.8%) positive for non-variants and 40,828 (9.7%) positive for a variant of concern.
Price Action: AZN shares are up 0.14% at $58.04 during the premarket session on the last check Friday.
Photo by Wilfried Pohnke from Pixabay
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.